Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain ...

RBC Capital maintained a Sector Perform rating on Regeneron, with a price target of $662, following challenges in the itepekimab program. A survey conducted by RBC Capital indicated investor interest ...